Review of LGD-4033 (LIGANDROL)
09March 9, 2023
LGD-4033, also known as Ligandrol, is an investigational selective androgen receptor modulator (SARM) currently undergoing research evaluation for its potential applications in laboratory studies of muscle tissue preservation and bone density enhancement. Research suggests that unlike anabolic androgenic steroids and anabolic steroids, LGD-4033 demonstrates a more favorable profile in laboratory settings with fewer observed effects while maintaining comparable efficacy in performance measurements within controlled research environments. Traditional anabolic steroids are known for their androgenic side effects, which can negatively impact HDL cholesterol levels and overall lipid profiles.
LGD-4033 is available from Loti Labs as a research-grade substance for laboratory investigations. This compound is formulated as a liquid in 10 mg per ml vials and is intended exclusively for research purposes. It should be noted that this substance is not intended for consumption and should only be used in controlled research settings.
WHAT IS LGD-4033 (LIGANDROL) – A SELECTIVE ANDROGEN RECEPTOR MODULATOR
LGD-4033 represents an innovative nonsteroidal, oral SARM that research indicates binds to androgen receptors with high affinity and selectivity in laboratory studies.
In preclinical models, research suggests LGD-4033 has demonstrated anabolic activity in muscle tissue, anti-resorptive and anabolic activity in bone structures, and a robust selectivity for muscle versus prostate tissue within controlled laboratory conditions.
Unlike traditional anabolic compounds, research indicates selective androgen receptor modulators (SARMs) exhibit tissue-selective activities in experimental settings. Laboratory studies suggest they express anabolic effects in bone and muscle tissues without causing androgenic observations such as sebaceous gland hyperactivity and prostate enlargement. Research indicates that LGD-4033 may influence natural testosterone levels in test subjects, suggesting that appropriate post-research protocols might be necessary for hormonal equilibrium restoration in experimental models.
STRUCTURE OF LGD-4033 (LIGANDROL)
IUPAC Name: 4-[(2R)-2-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]pyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrile
Molecular Formula: C14H12F6N2O
Molecular weight: 338.25 g/mol
CAS number: 1165910-22-4
MECHANISM OF ACTION
Research indicates that LGD-4033 functions as a ligand that enters the cell through diffusion and attaches to the androgen receptor in the cytoplasm, forming a receptor/ligand complex. Laboratory studies suggest this complex translocates to the nucleus, where it binds to DNA and acts as a transcriptional regulator of androgen-responsive genes in experimental settings.
One of the key observations in laboratory research of LGD-4033 is its potential to influence bone mineral density measurements in experimental models, which researchers suggest might contribute to understanding bone structure maintenance.
Laboratory findings indicate the compound causes concentration-dependent alterations of total testosterone, sex hormone–binding globulin, high-density lipoprotein cholesterol, and triglyceride levels in research settings. Studies suggest follicle-stimulating hormone and free testosterone showed significant measurement changes at the 1 mg concentration only in controlled laboratory environments.
Research data indicates LGD-4033 demonstrates a prolonged elimination half-life (24–36 hours) in laboratory analyses.
LGD-4033 (LIGANDROL) EFFECTS ON LEAN MUSCLE MASS
Research on LGD-4033 suggests several potential applications:
Research suggests increased lean body mass in laboratory models
Preliminary investigations have demonstrated that LGD-4033 can potentially influence lean tissue development, with research indicating an approximate increase of 2.67 pounds over a three-week observation period.
Research suggests improved physical function markers
Potential applications in muscle tissue preservation studies
Research indicates influence on HDL cholesterol parameters
Studies suggest decrease in Triglyceride measurements
Research observations include potential increases in bone mineral density, periosteal bone formation, and femur bending strength in preclinical models
LGD-4033’s role as a selective androgen receptor modulator (SARM) makes it a subject of interest for its ability to selectively target androgen receptors in muscle and bone tissues. This selective activation leads to anabolic effects that promote muscle growth and increase lean muscle mass without the full spectrum of androgenic effects often associated with traditional anabolic androgenic compounds.
In addition to muscle mass enhancement, LGD-4033’s potential impact on bone mineral density suggests it may aid in addressing muscle wasting and muscle atrophy in research settings. Its influence on physical performance and muscle strength further aligns with its potential as a mass building SARM in laboratory investigations.
The compound’s effect on lipid profiles, particularly HDL cholesterol and triglycerides, indicates a broader scope of metabolic influence that warrants further investigation. These properties, combined with its potential to improve bone and muscle tissues, position LGD-4033 as a promising candidate for future research and therapeutic applications in muscle building and preservation studies.
CLINICAL TRIALS AND RESEARCH
Studies on LGD-4033
LGD-4033 has been the subject of several investigational studies aimed at evaluating its research profile and efficacy in various experimental conditions. In a Phase I investigation, research subjects received quantities of 0.1, 0.3, and 1.0 mg/day for 21 days. The results from this preliminary research were noteworthy, suggesting that LGD-4033 was well-tolerated in laboratory settings and demonstrated a quantity-dependent relationship with lean tissue development and physical performance metrics.
Another significant investigation involved studies on tissue preservation in cancer-related models. In this Phase II investigation, LGD-4033 was compared to a control substance. The findings indicated that LGD-4033 significantly influenced lean tissue measurements and physical function parameters compared to the control, highlighting its potential applications in tissue preservation research.
Additionally, LGD-4033 has been examined in the context of bone density research. In a Phase II investigation involving postmenopausal models of osteoporosis, research quantities of 1.0 mg/day were administered for 12 weeks. The collected data demonstrated that LGD-4033 influenced bone mineral density measurements and fracture risk factors, showcasing its potential research applications for skeletal tissue investigations.
SIDE EFFECTS OF LGD-4033
LGD-4033, like any other selective androgen receptor modulator (SARM), can cause side effects, some of which can be serious. The most common side effects observed in research settings include:
Testosterone Suppression: Research indicates that LGD-4033 can suppress natural testosterone production, leading to decreased energy levels and libido in experimental models.
Liver Toxicity: Laboratory studies suggest that LGD-4033 can cause liver damage, especially at high doses, highlighting the importance of monitoring hepatic markers in research subjects.
Androgenic Activity: Although LGD-4033 is a selective androgen receptor modulator, high doses in research settings can lead to androgenic side effects such as hair loss and acne.
Decreased HDL Cholesterol: Research findings indicate that LGD-4033 can decrease HDL (good) cholesterol levels, which may increase the risk of heart disease in experimental models.
Increased Risk of Prostate Issues: Studies suggest that LGD-4033 can increase the risk of prostate issues, such as prostate cancer, especially in subjects with a history of prostate problems.
It’s essential to note that the severity and frequency of these side effects can vary depending on the individual, dosage, and duration of use in research settings.
DOSAGE AND CYCLES
The optimal dosage and cycle length for LGD-4033 can vary depending on the research objectives and the experience level of the investigator. Here are some general guidelines based on current research:
Beginner: 5-10mg per day for 8-12 weeks
Intermediate: 10-20mg per day for 12-16 weeks
Advanced: 20-30mg per day for 16-20 weeks
It’s essential to start with a low dose and gradually increase it as needed, under the guidance of a healthcare professional. Following a post-cycle therapy (PCT) protocol after completing a cycle of LGD-4033 is crucial to restore natural testosterone production and minimize side effects.
LGD-4033 VS OTHER SARMS
Comparison with Other SARMs
LGD-4033 stands out among selective androgen receptor modulators (SARMs) in research environments for its binding profile and research characteristics. When compared to other extensively studied SARMs like Ostarine and RAD-140, laboratory analysis suggests LGD-4033 exhibits a higher affinity for androgen receptors and a more pronounced effect on protein synthesis pathways.
Ostarine, while effective in research models for lean tissue development and bone density parameters, is considered to have milder laboratory effects than LGD-4033. It is often selected for moderate research applications with different experimental parameters. However, for research requiring more substantial tissue development observations, LGD-4033’s higher receptor activity makes it an interesting candidate for investigation.
RAD-140, known for its strong binding profile, also demonstrates significant effects in tissue development studies. However, research suggests different experimental considerations. In contrast, LGD-4033 is regarded as having a distinct research profile among SARMs, with different laboratory observations, making it a compelling subject for various research applications.
HALF-LIFE AND ADMINISTRATION
LGD-4033 has a half-life of 24-36 hours, which means it can be administered once daily in research settings. It’s essential to take LGD-4033 at the same time every day to maintain consistent levels in the body. While LGD-4033 can be taken with or without food, it’s recommended to take it with food to minimize stomach upset in experimental models.
LGD-4033 RESEARCH PARAMETERS AND PROTOCOLS
Recommended Research Parameters and Observation Periods
When establishing research parameters for LGD-4033, laboratory investigations typically employ quantities ranging from 1-10 mg/day, with observation periods commonly spanning 8-12 weeks. The optimal research parameters and cycle duration may vary based on specific research objectives and experimental design.
For initial investigations, starting with quantities of 1-5 mg/day over an 8-week observation period is common in the literature. This allows researchers to observe the compound’s influence on experimental models while documenting moderate changes in lean tissue development and bone mineral density.
More advanced research protocols may employ higher quantities of 5-10 mg/day, extending the observation period to 12 weeks. This approach can facilitate more comprehensive data collection on tissue development and bone density parameters, though with potentially different experimental considerations. Careful monitoring of all research variables and adjusting parameters accordingly remains crucial to ensure scientific validity and experimental integrity.
By adhering to established research protocols, investigators can maximize data collection on LGD-4033 while maintaining appropriate experimental controls, making it a valuable addition to selective androgen receptor modulator research.
LGD-4033 (LIGANDROL) RESEARCH OBSERVATIONS INCLUDING HEPATIC CONSIDERATIONS
Laboratory observations commonly documented in LGD-4033 research include:
Potential hepatic stress markers – research suggests diffuse cutaneous irritation, yellowing of specimen tissues, colorless biological waste samples, intermittent abdominal region discomfort that correlates with digestive disruption, mass reduction in test subjects
Alterations in lipid profiles within blood chemistry analyses
Indicated correlation with cardiovascular stress markers
Vascular complications in research models
CASE REPORT: A REAL-WORLD EXAMPLE
A 32-year-old male bodybuilder reported significant gains in lean muscle mass and strength after using LGD-4033 for 12 weeks. He started with a dosage of 10mg per day and gradually increased it to 20mg per day over the course of the cycle. He reported no significant side effects, except for mild testosterone suppression, which was resolved with a post-cycle therapy protocol. His results were:
Lean Muscle Mass: +10kg
Strength: +20kg
Body Fat Percentage: -5%
It’s essential to note that individual results may vary, and LGD-4033 should only be used under the guidance of a healthcare professional.
LOOKING FOR WHERE TO PURCHASE LGD-4033 (LIGANDROL) FOR RESEARCH PURPOSES
When conducting searches for research compounds online, it is fundamentally important to source materials from established and credentialed laboratories to ensure the scientific integrity of your experimental protocols.
Loti Labs provides cost-effective research substances accompanied by comprehensive analytical verification documentation. Our technical support team offers extensive assistance for research inquiries, and we maintain a comprehensive return protocol for researchers who acquire LGD-4033 research compound.
Visit our laboratory website or communicate with our research team today to procure LGD-4033 for your scientific investigations.
References:
Basaria S, Collins L, Dillon EL, Orwoll K, Storer TW, et al. (Jan 2013). “The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men”. J Gerontol A Biol Sci Med Sci. 68 (1): 87–95. doi:10.1093/gerona/gls078. PMC 4111291. PMID 22459616.
“Ligand Presents New Preclinical Data on its Lead SARM Molecule LGD-4033 at the Gerontological Society of America Annual Meeting” (Press release). San Diego: Ligand Pharmaceuticals. November 20, 2009. Archived from the original on November 23, 2014. Retrieved November 23, 2014.
Barbara M, Dhingra S, Mindikoglu AL. Ligandrol (LGD-4033)-Induced Liver Injury. ACG Case Rep J. 2020 Jun 11;7(6):e00370. doi: 10.14309/crj.0000000000000370. PMID: 32637435; PMCID: PMC7304490.
